Lucius Dasatinib™ | Instruction Manual v.2.0

Designation: Targeted Kinase Inhibition System
Model: Lucius Dasatinib
Strength: 20mg / 50mg / 70mg / 100mg
Indication: Philadelphia Chromosome–Positive (Ph+) Leukemias

1. SYSTEM OVERVIEW

The Lucius Dasatinib unit is a second-generation, orally bioavailable tyrosine kinase inhibitor (TKI) engineered for precision targeting of BCR-ABL1 and SRC-family kinases. It is indicated for use in cases of:

• Chronic Myeloid Leukemia (CML) in chronic, accelerated, or blast phase

• Philadelphia chromosome–positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Mechanism of Action:
Binds with high affinity to the ATP-binding domain of BCR-ABL, inhibiting uncontrolled proliferation and inducing apoptosis in malignant cells.

2. INITIALIZATION & DOSING

Recommended Loading Sequence:

• Chronic Phase CML: 100mg once daily

• Advanced Phase CML / Ph+ ALL: 140mg once daily

Administration Protocol:

• Administer whole with water. Do not crush or split.

• May be taken with or without food.

• Consistent daily timing is recommended.

Dose Modification Modules (e.g., 20mg/50mg tablets):
Enable fine-tuned dose adjustments in response to toxicity or drug interactions.

3. MONITORING & FEEDBACK LOOPS

Routine Surveillance Required:

• Hematologic: CBC weekly × 2 months, then monthly

• Biochemical: Liver function, electrolytes (Ca²⁺/Mg²⁺/K⁺)

• Cardiopulmonary: Echocardiogram, symptoms of effusion/dyspnea

• Molecular: BCR-ABL1 RT-PCR every 3 months

Performance Metrics:

• Major Molecular Response (MMR) expected within 12–24 months

4. ADVERSE EVENT PROTOCOLS

5. DRUG INTERACTION ALGORITHMS

Contraindicated Combinations:

• Strong CYP3A4 inhibitors (e.g., ketoconazole)

• Strong CYP3A4 inducers (e.g., rifampin)

Use With Caution:

• Anticoagulants / Antiplatelets

• Proton-pump inhibitors

6. SAFETY PROTOCOLS

• Pregnancy / Lactation: Contraindicated (Category D)

• Hepatic/Renal Impairment: Use with caution; monitor closely

• Missed Dose: Do not double next dose. Resume normal schedule.

7. STORAGE & HANDLING

• Store at 20°–25°C (68°–77°F)

• Protect from moisture and light

• Keep in original container

8. DISCONTINUATION CRITERIA

• Loss of response

• Intolerable / unmanageable toxicity

• Progression to blast crisis

• 
  WeChat：+852 61905607
  WeChat：yindu7689